The Federal Government (FG) has secured a monumental price reduction for the twice-yearly HIV prevention injection, lenacapavir. The cost per person was successfully negotiated down from $28,000 to just $40, making a life-saving treatment accessible to millions.
This breakthrough was announced by Mrs Toyin Aderibigbe, Deputy Director, Public Relations and Protocol Division, at the National Agency for the Control of AIDS (NACA). Dr Temitope Ilori, Director-General of NACA, joined global leaders at the 80th United Nations General Assembly (UNGA) to finalize the deal.
Dr. Ilori expressed strong optimism that the drastic price drop will make the medicine available across Nigeria and other developing countries. The drug, which is up to 100 per cent effective in preventing new HIV infections, provides a powerful new tool against the epidemic. “Today marks a milestone in our fight against HIV in Nigeria and globally,” Dr. Ilori stated, affirming the collaborative effort.
“Through this landmark access agreement, we are unlocking affordable access to lenacapavir, a transformational new HIV prevention option that offers longer protection, greater convenience, and renewed hope to millions at risk.
” This agreement ensures that this breakthrough innovation does not remain a privilege for the few. It pairs innovation with equity, laying the foundation for broad, long-lasting impact for those who need it most.”
The announcement underscores Nigeria’s commitment to expand access to prevention, strengthen health systems, and accelerate progress toward ending HIV as a public health threat by 2030.
The breakthrough was made possible through strong collaboration with UNITAID, the Clinton Health Access Initiative (CHAI), Wits RHI, Dr. Reddy’s Laboratories Ltd. (DRL), and
The Gates Foundation.
Nigeria’s participation highlights its resolve not only to be innovative but to deepen global partnerships and secure a healthier and more resilient future for its people.
